Patients with stage IV (n = 14) were further compared with 115 stage IV patients comprising 38 patients with EGFR mutation treated with erlotinib and/or gefitinib and/or afatinib (+/− cetuximab), 13 patients with ALK rearrangement treated with crizotinib and/or ceritinib, 32 patients with KRAS mutations and 32 patients with squamous-cell carcinoma and FGFR1 amplification (see Supplementary Figure 1). Here, FGFR1 is linked to squamous cell carcinoma.